Homehealthcare News

    As Lupin forays into diagnostics, here's what Credit Suisse says

    healthcare | IST

    As Lupin forays into diagnostics, here's what Credit Suisse says

    Mini

    Credit Suisse said Lupin's move to enter the diagnostics space is increasing the competitive intensity. 

    Credit Suisse said Lupin's move to enter the diagnostics space is increasing competitive intensity.  The pharmaceutical company is close to launching full-fledged operations in diagnostics in the western and eastern parts of the country, pioneering the trend of drug makers diversifying into diagnostics.
    Lupin has set up a national reference lab in Navi Mumbai. CNBC-TV18 had reported the news on Thursday.
    Until now, pharma companies are not present in the diagnostic space despite having good connections with doctors.
    In fact, it is an asset-light model, which can potentially attract more pharma companies into the space. The doctor relationships are potentially synergistic between pharma and diagnostic businesses. So the prescriber network, in fact, could be leveraged, according to Credit Suisse.
    Lupin is scouting for franchise partners. The plan is to set up collection networks across the western and eastern regions of the country, and has already hired an experienced team. Diagnostics will be a part of its wholly-owned subsidiary, Lupin Healthcare.
    On Metropolis Healthcare, Credit Suisse pointed out that competition is increasing in its home market of Mumbai. The brokerage has an 'underperform' rating on Metropolis Healthcare with a target price of Rs 1,700.
    Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.
    next story

      Market Movers

      View All
      CompanyPriceChng%Chng